or Try an Advanced Search...

    Technical Analysis for AKBA - Akebia Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 1.79 -1.65% -0.03
    AKBA closed down 1.65 percent on Wednesday, November 20, 2024, on 63 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical AKBA trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    20 DMA Support Bullish -1.65%
    NR7 Range Contraction -1.65%
    NR7-2 Range Contraction -1.65%
    20 DMA Support Bullish -0.56%
    1,2,3 Pullback Bullish Bullish Swing Setup -0.56%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.56%
    Older End-of-Day Signals for AKBA ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 16 hours ago
    Possible NR7 about 18 hours ago
    60 Minute Opening Range Breakdown about 20 hours ago
    20 DMA Resistance about 21 hours ago
    20 DMA Support about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    AKBA Chart by TradingView
    Basic chart:

    Profile

    Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Kidney Disease Dialysis Anemia Chronic Kidney Disease Kidney Hypoxia Inducible Factors

    Is AKBA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Q3 2024 Earnings: Hold Akebia Therapeutics
    Nov 14 Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
    Nov 12 Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
    Nov 9 Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
    Nov 8 Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
    Nov 7 Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
    Nov 7 Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
    Nov 7 Akebia Therapeutics: Q3 Earnings Snapshot
    Nov 7 Akebia GAAP EPS of -$0.10, revenue of $37.4M
    Nov 7 Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
    See more AKBA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.48
    52 Week Low 0.8
    Average Volume 1,827,454
    200-Day Moving Average 1.41
    50-Day Moving Average 1.53
    20-Day Moving Average 1.80
    10-Day Moving Average 1.87
    Average True Range 0.10
    RSI (14) 55.16
    ADX 35.89
    +DI 23.24
    -DI 17.49
    Chandelier Exit (Long, 3 ATRs) 1.72
    Chandelier Exit (Short, 3 ATRs) 1.69
    Upper Bollinger Bands 2.05
    Lower Bollinger Band 1.55
    Percent B (%b) 0.48
    BandWidth 28.04
    MACD Line 0.09
    MACD Signal Line 0.11
    MACD Histogram -0.023
    Fundamentals Value
    Market Cap 337.22 Million
    Num Shares 188 Million
    EPS -0.31
    Price-to-Earnings (P/E) Ratio -5.77
    Price-to-Sales 1.61
    Price-to-Book 4.12
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.85
    Resistance 3 (R3) 1.85 1.84 1.84
    Resistance 2 (R2) 1.84 1.82 1.84 1.84
    Resistance 1 (R1) 1.81 1.81 1.81 1.81 1.83
    Pivot Point 1.80 1.80 1.79 1.80 1.80
    Support 1 (S1) 1.77 1.78 1.77 1.77 1.75
    Support 2 (S2) 1.76 1.77 1.76 1.74
    Support 3 (S3) 1.73 1.76 1.74
    Support 4 (S4) 1.73